good on any construction??, page-6

Rev I will try and make a genuine effort to answer what I see as a genuine question.

Positive. ACL Oncology could be a major winner. A pure oncology play that listed on the Nasdaq, had spectacular P3 results and a whole range of potential application sot other cancers could be hugely rewarding to shareholders. Unfortunately we used to own 100% of this but will in future only own some pro-rata share of it.

Negative. ACL Fonda is a dead duck. One product. Inevitable decline of income to virtually zero as new generics appear and price dilution kicks in. Eventually its an empty shell worst case. Along the way shareholders have received their capital back as taxable income.

Why is the price going up today. Simple. RBS et al have achieved their objective. Having smashed the share price to make funding possible on only the most unfavourable of terms they dont need to cap anymore. ACL at 25 cents is pretty attractive to a new shareholder 1) all the dilution is done 2) its funded 3)it gets you a piece of the oncology pie and 4) you get a yield stock you can punt later to reduce your entry costs.

Hell if I was bleeding from every orifice because of the ones I already own I buy ACL today.